Global Diverticulitis Disease Market Growth Accelerates: Strategic Forecast Predicts $2.91 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Diverticulitis Disease Industry Market Size Be by 2025?
The expansive reach of the diverticulitis affliction industry has experienced substantial forward momentum lately, projected to climb from a valuation of $1.85 billion in the current year of 2024 to reach $2.02 billion by 2025, reflecting a consistent yearly expansion rate approximating 9.3%; this robust historical expansion phase is fundamentally linked to demographic shifts toward older age groups, evolving nutritional patterns, the widespread prevalence of obesity, and concurrent breakthroughs in diagnostic imaging technologies.

What's the Long-Term Growth Forecast for the Diverticulitis Disease Market Size Through 2029?
Anticipation surrounds the diverticulitis disease sector, forecasting substantial expansion over the forthcoming years, with projections indicating a market valuation reaching $2.91 billion by 2029, underpinned by a compound annual growth rate (CAGR) of 9.5%; this sustained upswing is primarily fueled by advancements in colonoscopy and endoscopy techniques, heightened public cognizance regarding the condition, a rise in the utilization of less invasive surgical interventions, and the move toward more individualized treatment regimens, while key influencers shaping this period involve a greater emphasis on preventative strategies, the introduction of superior diagnostic instrumentation, the adoption of integrated care frameworks, and evolving healthcare legislation.

View the full report here:
https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

What Are the Key Growth Drivers Fueling the Diverticulitis Disease Market Expansion?
The escalating incidence of smoking dependency is anticipated to be a primary catalyst for the expansion of the market concerning diverticulitis illness in the future. This upward trend in smoking addiction is fueled by various factors, including intense promotional activities, societal normalization, elevated stress levels, and the inherent addictive properties of nicotine. Furthermore, the widespread accessibility of vaping products and e-cigarettes, coupled with external social pressures and influence from peers, particularly among younger demographics, serves to elevate smoking figures. Smoking directly contributes to the increased need for diverticulitis management because it elevates the probability of acquiring diverticular ailments through compromised colonic blood flow, often resulting in more serious health outcomes, thereby amplifying the requisite need for diagnostic procedures and subsequent treatment modalities. Illustratively, Statistics Canada reported in July 2022 that cigarette manufacturing in Canada saw a rise of 5.8 percent when measured against the figures from June 2021, and concurrently, the aggregate of cigarettes purchased escalated by 1.3 percent from May 2022, culminating in a total of 1.4 billion units sold during June 2022. Consequently, the increasing frequency of smoking addiction stands as a significant driver for the progress observed within the diverticulitis disease market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12990&type=smp

What Are the Key Trends Driving Diverticulitis Disease Market Growth?
Key players within the diverticulitis illness sphere are concentrating on creating novel therapeutic agents and securing regulatory clearances to solidify their competitive standing. This pursuit of drug innovation promises the advent of superior management strategies for diverticulitis, which ought to lessen complication potential and enhance recovery for those affected. A notable event occurred in April 2023 when the US Food and Drug Administration, a federal regulatory body in the United States, granted approval to Seres' microbiota-based pharmaceutical for persistent intestinal ailments. This specific medication targets and aims to circumvent the relapse of Clostridioides difficile (C. diff.) infections among adult populations aged eighteen and beyond. The endorsement given to Vowst followed the success of a clinical investigation involving 346 individuals suffering from recurring CDI; the study demonstrated that administering Vowst substantially lowered the probability of infection recurrence when contrasted with placebo administration. In terms of delivery, this medicine is administered orally and relies on microbiota comprised of Firmicutes spores, recognized components that foster a robust gut environment capable of inhibiting C. diff. proliferation.

How Is the Diverticulitis Disease Market Segmented?
The diverticulitis diseasemarket covered in this report is segmented -

1) By Type: Uncomplicated; Complicated
2) By Diagnosis: Computed Tomography (CT) Scan; Ultrasound; Urine Test; Blood Test
3) By Treatment: Medications; Surgery; Supportive care; Penicillin Antibiotic; Antibiotics; Dietary Supplements; Intravenous (IV) Fluids
4) By End-User: Specialty Centers; Hospitals; Research centers

Subsegments:
1) By Uncomplicated: Outpatient Treatment; Dietary Management; Antibiotic Therapy
2) By Complicated: Hospitalization; Surgical Intervention; Intravenous Antibiotics; Abscess Drainage

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12990&type=smp

Which Companies Are Leading the Charge in Diverticulitis Disease Market Innovation?
Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

Which Regions Are Leading the Global Diverticulitis Disease Market in Revenue?
North America was the largest region in the diverticulitis disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diverticulitis disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12990

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.